About Renerva
Renerva is a Healthcare company based in Pittsburgh (United States) founded in 2017 by Lorenzo Soletti. Implants for peripheral nerve repair are developed for injury treatment. Renerva has raised $1.28 million across 8 funding rounds from investors including NIH, HHS and America’s Seed Fund. Its chief executive, as recorded, is Lorenzo Soletti. Renerva offers products and services including Implantable Technologies. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its legal entity is Renerva LLC. Its competitors include Avation, Tulavi Nerve Therapeutics and BioCircuit; 3 of its 3 listed competitors have raised funding.
Company details
Renerva was founded in 2017 and is based in Pittsburgh, United States. Focus is placed on the medical device sector, where implants are developed for peripheral nerve repair procedures. These implants address nerve injuries and aim to enhance nerve function. Operations involve research and development in regenerative medicine, with activities centered on therapeutic solutions for peripheral nervous system conditions.
- Headquarters Pittsburgh, United States
- Founders Lorenzo Soletti
- SectorsHealthcare
- Email••••••••
- Website renerva.com
- Social LinkedIn
- Legal Name Renerva Llc
- Total Equity Funding$1.28M (USD)
in 8 rounds
- Latest Funding Round$324.82K (USD), Seed
Sep 2025
- InvestorsNIH
& 3 more
Products & Services of Renerva
Renerva offers a comprehensive portfolio of products and services, including Implantable Technologies.
Devices for improving peripheral nerve repair outcomes
Funding Insights of Renerva
Renerva has successfully raised a total of $1.28M across 8 strategic funding rounds. The most recent funding activity was a Seed round of $324.82 thousand completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.28M
- Total Rounds 8
- Last Round Seed — $324,820
- First Round $617,305
(Jun 2018)
- Investors Count 4
All 8 funding rounds of Renerva with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2025 | $324,820 | Seed | – | – | – |
| Sep 2024 | $499,999 | Grant | – | – | |
| Jul 2024 | $335,000 | Seed | – | – | – |
| Sep 2023 | $494,955 | Grant | – | – | |
| Sep 2019 | $274,315 | Grant | – | – | |
| Jul 2019 | $500,000 | Grant | – | – | |
| Dec 2018 | $2.4M | Grant | – | – | |
| Jun 2018 | $617,305 | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in Renerva
Renerva has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and America’s Seed Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund backed by the US Government | seedfund.nsf.gov | Alexandria, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Military forces are provided by the U.S. Department of Defense for national security. | defense.gov | Washington, D.C., United States |
Investor details for Renerva
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Renerva
2 people are tracked at Renerva (1 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Lorenzo Soletti | Co-Founder, CEO & President | Leadership |
Anne Faust | Operations Manager | Team |
Complete people profiles for Renerva
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Renerva
3 dated milestones of Renerva across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Renerva is founded.
- Funding First funding round of $617K.
- Funding Latest funding round, Seed, of $325K.
Competitors of Renerva
Renerva has 3 listed competitors in our database, 3 of them funded. They include Avation, Tulavi Nerve Therapeutics and BioCircuit.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| avation.com | 1999 | Columbus, United States | $34.92M | Wearable tibial nerve stimulation device treats overactive bladder symptoms. | ||
| tulavi.com | 2020 | Mountain View, United States | $4M | Therapeutic devices for neurally mediated diseases are developed. | ||
| biocircuit.com | 2016 | Atlanta, United States | $13.65M | Non-invasive electrophysiology devices are developed to monitor peripheral nerves. |
Detailed competitors of Renerva
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Renerva (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Renerva
Complete news archive for Renerva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Renerva
Renerva was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Renerva is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Lorenzo Soletti is the CEO of Renerva, as recorded in our data. They have also founded this company.
Renerva is a funded company, having raised a total of $1.28M across 8 funding rounds to date. The company's 1st funding round was a Seed of $617.31K, raised on Jun 2018.
Renerva was founded in 2017 and is based in Pittsburgh, United States. Focus is placed on the medical device sector, where implants are developed for peripheral nerve repair procedures. These implants address nerve injuries and aim to enhance nerve function. Operations involve research and development in regenerative medicine, with activities centered on therapeutic solutions for peripheral nervous system conditions.
Renerva's top competitors include Avation, Tulavi Nerve Therapeutics and BioCircuit.
Renerva offers Implantable Technologies.
Renerva has 4 investors. Key investors include NIH, HHS, America’s Seed Fund, and U.S. Department of Defense.
Renerva operates through Renerva Llc.